0.00Open0.71Pre Close0 Volume19 Open Interest1.00Strike Price0.00Turnover608.33%IV86.19%PremiumFeb 21, 2025Expiry Date0.00Intrinsic Value100Multiplier64DDays to Expiry0.71Extrinsic Value100Contract SizeAmericanOptions Type-0.0587Delta0.0220Gamma2.96Leverage Ratio-0.0049Theta-0.0010Rho-0.17Eff Leverage0.0010Vega
Brainstorm Cell Therapeutics Stock Discussion
@MARKET-TEST-DUMMY 48 hours ago.
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
Tuesday, 3rd December at 7:00 am
NEW YORK, Dec. 3, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) for patent applica...
No comment yet